Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the rate of molecular remissions (MolR)
assessed by ASO-RQ-PCR technique after induction treatment with bortezomib and dexamethasone
(Vel/Dex) prior to high-dose therapy with melphalan and autologous stem cell transplantation
(HDT-ASCT), and after HDT-ASCT in patients with multiple myeloma.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tampere University Hospital
Collaborators:
Central Hospital of Kanta-Hame Helsinki University Central Hospital Janssen-Cilag Ltd. Jyväskylä Central Hospital Kanta-Häme Central Hospital Kuopio University Hospital Oulu University Hospital Päijänne Tavastia Central Hospital Seinajoki Central Hospital Turku University Hospital